Recombinant Human TNF-β 0 ReviewsSubmit a Review Product Details Catalog Number: 300-01B Description: TNF-β is a potent mediator of inflammatory and immune responses. It belongs to the TNF family of ligands, and signals through TNFR1 and TNFR2. TNF-β is produced by activated T and B lymphocytes, and has similar activities to TNF-α. Like TNF-α, TNF-β is involved in the regulation of various biological processes, including cell proliferation, differentiation, apoptosis, lipid metabolism, coagulation, and neurotransmission. TNF-β is secreted as a soluble polypeptide, but can form heterotrimers with lymphotoxin-β, which effectively anchors the TNF-β to the cell surface. TNF-β is cytotoxic to a wide range of tumor cells. Recombinant Human TNF-β is a secreted 172 amino acid protein (18.6 kDa) which forms an active non-disulfide-linked homotrimer structure in solution. Source: E.coli Synonyms: Tumor Necrosis Factor-β, TNFSF1B, Lymphotoxin-alpha (LT-α) AA Sequence: MLPGVGLTPS AAQTARQHPK MHLAHSTLKP AAHLIGDPSK QNSLLWRANT DRAFLQDGFS LSNNSLLVPT SGIYFVYSQV VFSGKAYSPK ATSSPLYLAH EVQLFSSQYP FHVPLLSSQK MVYPGLQEPW LHSMYHGAAF QLTQGDQLST HTDGIPHLVL SPSTVFFGAF AL Purity: ≥ 98% by SDS-PAGE gel and HPLC analyses. Biological Activity: The ED50 as determined by the cytolysis of murine L929 cells in the presence of Actinomycin-D is ≤ 0.05 ng/ml, corresponding to a specific activity of ≥ 2 x 107 units/mg. Calculated Molecular Weight: 18.6 kDa Accession Number: P01374 Gene ID: 4049 Endotoxin: Endotoxin level is < 0.1 ng/ug of protein (< 1 EU/ug) Note: 1mg will be provided as 2x500μg. Cross Reactivity Cited in References: Human, Mouse References PubMed SDS CoA Search Product Line Country Of Origin: USA Not for human use. Research Interest Angiogenesis/Cardiovascular Apoptosis Immune System Inflammation Lipid Metabolism Neurobiology Stem Cells & Differentiation TNF Superfamily Allergy Recent Citations First Author Chan, L C Title IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. Citation The Journal of Clinical Investigation; 129(8) pg3324-3338 PubMed ID 31305264 First Author Park, M K Title Cell Type-Specific Interferon-γ-mediated Antagonism of KSHV Lytic Replication. Citation Scientific Reports; 9(1) pg2372 PubMed ID 30787356 First Author Shee, K Title Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer. Citation The Journal of Experimental Medicine; 215(3) pg895-910 PubMed ID 29436393
